Clinical trials: Lower Urinary Tract Symptoms
Urinary Stress Incontinence
Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence
The study is a comparison of the efficacy and safety of duloxetine and pelvic floor muscle training with that of placebo in patients with moderate to severe stress urinary incontinence
- Trial name
- NCT00190606
- Testing
- Duloxetine, Pelvic Floor Muscle Training (PFMT), Imitation PFMT
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Overactive Bladder
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
- Trial name
- NCT00350636
- Testing
- Oxybutynin topical gel
- Where
- 63 sites in United States
- Volunteers
- 789 people
- Sponsor
- Watson Pharmaceuticals
Urinary Incontinence
Investigation of the Ability of the TENA SmartCare Change Indicator to Reduce the Number of Manual Checks Between Changes of Absorbing Incontinence Products
The purpose of this post market clinical investigation is to demonstrate the performance and safety of the TENA SmartCare Change Indicator.
- Trial name
- NCT04846270
- Testing
- TENA SmartCare Change Indicator
- Where
- Poland
- Volunteers
- 35 people
- Sponsor
- Essity Hygiene and Health AB
Overactive Bladder, Detrusor Overactivity
A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function
The purpose of this study is to assess if the study drug, Vardenafil (approved by Health Authorities is available on the market for treatment of erectile dysfunction) has an effect on bladder function and micturition frequency.
- Trial name
- NCT00478881
- Testing
- Vardenafil HCl (Levitra, BAY38-9456)
- Where
- 55 sites in Belgium, Canada and 11 more
- Volunteers
- 397 people
- Sponsor
- Bayer
Nocturia
Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Men
The purpose of the study is to investigate the efficacy and safety of two different dose levels of desmopressin orally disintegrating tablets against placebo for the treatment of nocturia in adult men during 12 weeks treatment
- Trial name
- NOC (NCT01694498)
- Testing
- A: Desmopressin 25 µg, B. Desmopressin 50 µg
- Where
- 35 sites in Japan
- Volunteers
- 183 people
- Sponsor
- Ferring Pharmaceuticals
Multiple Sclerosis, Overactive Detrusor
Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity
The objective of this study is to explore the effects of darifenacin in patients with multiple sclerosis and neurogenic detrusor overactivity.
- Trial name
- NCT00845338
- Testing
- Darifenacin (BAY79-4998)
- Where
- 15 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Bayer
Overactive Bladder, Neurogenic Detrusor Overactivity
Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder
The purpose of this study is to evaluate blood levels of solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after taking a single oral dose.
- Trial name
- NCT01539707
- Testing
- Solifenacin succinate suspension 5 mg
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Inc
Female Stress Urinary Incontinence, Mixed Incontinence, Urge and Stress
Er:YAG Laser Treatment for Female Stress and Mixed Urinary Incontinence (IncontiLase)
The purpose of this study was to evaluate the effect of a non-invasive Er:YAG thermal laser therapy in treating female stress and mixed urinary incontinence.
- Trial name
- NCT02418299
- Testing
- IncontiLase Er:YAG laser treatment
- Volunteers
- 175 people
- Sponsor
- Juna d.o.o.
Overactive Bladder
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Overactive bladder (OAB) is a syndrome characterized by symptoms of a sudden need to urinate with or without incontinence (leaking).
- Trial name
- NCT01868516
- Testing
- dexmecamylamine
- Where
- 125 sites in United States
- Volunteers
- 1,635 people
- Sponsor
- Targacept Inc.
Urinary Bladder, Overactive
Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life
Evaluate the effect of VESIcare® on symptom bother for subjects with OAB
- Trial name
- VIBRANT (NCT00573508)
- Testing
- Solifenacin Succinate
- Where
- 59 sites in United States
- Volunteers
- 768 people
- Sponsor
- Astellas Pharma Inc
Stress Urinary Incontinence, Intrinsic Sphincter Deficiency
Post Market Clinical Study to Evaluate a Mid-Urethral Vaginal Tape Procedure With a Pre-Pubic Delivery Approach, for the Treatment of Stress Urinary Incontinence
The pre-pubic approach of the tension free vaginal sling placement is a new approach in the treatment of SUI. The retropubic approach of the tension free vaginal sling is the standard method of device delivery; in addition a…
- Trial name
- NCT00688298
- Testing
- Prefyx PPS™ System, Advantage ™ System
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Urinary Incontinence, Stress
Efficacy and Safety Stress Urinary Incontinence Study
Study F1J-MC-SBBT will examine the effect of duloxetine treatment in women with SUI. The inclusion and exclusion criteria of this Phase 3 study will ensure that all subjects have a clinical diagnosis of SUI.
- Trial name
- NCT00475358
- Testing
- Duloxetine
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Urinary Incontinence
Intermittent Catheterisation on the Bladder Mucosa of Healthy Volunteers With a Prototype Micro Hole Zone Catheter
This investigation is a randomized, single-blinded, parallel, single-center investigation. In total, up to 50 subjects (40 completers) were included and each subject had two test visits overseen by the Principal Investigator…
- Trial name
- CP341 (NCT05224544)
- Testing
- Investigational prototype device, Comparator device
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Coloplast A/S
Overactive Bladder (OAB)
Tensi+ for Treating Overactive Bladder
The purpose of the study is to evaluate the safety and effectiveness of the Tensi+ device using Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) for treating patients suffering from OAB symptoms urinary frequency…
- Trial name
- NCT07300904
- Testing
- Tensi+
- Where
- 3 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Stimuli Technology
Stress Urinary Incontinence
Solace Stress Urinary inContinence Control Efficacy and Safety Study
The SUCCESS Trial is designed to determine whether the Solace Bladder Control System is safe and effective for the treatment of Stress Urinary Incontinence (SUI) in adult females.
- Trial name
- SUCCESS (NCT02210273)
- Testing
- Solace Bladder Control (Vesair) Balloon
- Where
- 20 sites in United States
- Volunteers
- 221 people
- Sponsor
- Solace Therapeutics, Inc.
Urinary Bladder, Overactive
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of YM178 against placebo and tolterodine to treat patients with symptoms of over active bladder.
- Trial name
- Blossom (NCT01604928)
- Testing
- YM178, tolterodine
- Where
- 30 sites in Belgium, Czechia and 4 more
- Volunteers
- 260 people
- Sponsor
- Astellas Pharma Europe B.V.
Stress Urinary Incontinence
Platelet-rich Fibrin Versus HIFU in Management of Stress Urinary Incontinence
Aim of the study is to compare effect of High Intensity Focused Ultrasound (HIFU) and platelet-rich fibrin in management of stress urinary incontinence. It is a randomized prospective study.
- Trial name
- NCT04144829
- Testing
- HIFU, Fibrin
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Intima Clinic
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms
This is an open-label extension study of another study protocol, MCS-2-TWN-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-TWN-a will be eligible for this study.
- Trial name
- MCS-2-TWN-c (NCT01002274)
- Testing
- MCS-2
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Stress Urinary Incontinence
Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence
The study will enroll only from the first 225 subjects who were randomly assigned to treatment in G201002 (irrespective of the treatment allocation, i.e., GTx-024 or placebo) and who have completed the 12-week treatment period…
- Trial name
- NCT03508648
- Testing
- GTx-024
- Where
- 46 sites in United States
- Sponsor
- GTx
Overactive Bladder
Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder
To investigate the safety of MEDITOXIN in female subjects with idiopathic overactive bladder compared with BOTOX
- Trial name
- NCT03371342
- Testing
- Meditoxin, Botox
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Medy-Tox